Orion

Orion ROE

The Return on Equity (ROE) of Orion (271560.KS) as of Nov 13, 2026 is 10.05 %. In the previous year, Return on Equity (ROE) was 15.11 % — a change of -33.51% (lower).

ROE

10.05 %

YoY

-33.51%

Last updated:

In 2025, Orion's return on equity (ROE) was 10.05 %, a -33.51% increase from the 15.11 % ROE in the previous year.

The Orion ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
9.95 KRW
Jan 1, 2019
13.29 KRW
Jan 1, 2020
14.62 KRW
Jan 1, 2021
11.66 KRW
Jan 1, 2022
15.36 KRW
Jan 1, 2023
13.16 KRW
Jan 1, 2024
15.11 KRW
Jan 1, 2025
10.05 KRW
The Orion ROE history
YEARROEYoY
10.05 %-33.51%
15.11 %+14.85%
13.16 %-14.35%
15.36 %+31.82%
11.66 %-20.29%
14.62 %+10.06%
13.29 %+33.53%
9.95 %+72.22%
5.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orion Stock analysis

What does Orion do? Orion Corp is a Finnish company that operates in the pharmaceutical industry. The company was founded in 1917 and is headquartered in Espoo, Finland. Orion Corp specializes in the development, manufacturing, and marketing of medications, as well as the diagnosis and treatment of diseases. As one of the leading pharmaceutical companies in Finland, Orion Corp is dedicated to researching and developing medications and medical devices to help doctors and their patients worldwide improve their quality of life. Orion Corp's business model focuses on selling prescription and over-the-counter medications, as well as manufacturing generic medications. Additionally, the company is involved in the diagnosis and treatment of diseases such as Parkinson's, cancer, and asthma. The company's main business is centered around three main divisions: pharmaceuticals, diagnostics, and animal health. Within these divisions, Orion Corp has various business areas. In the pharmaceutical division, the focus is on developing medications to combat Parkinson's, cancer, and asthma. The company has a strong product range of Parkinson's treatments that can alleviate symptoms and slow the progression of the disease. Furthermore, the company is involved in the development of cancer medications that can inhibit the growth of cancer cells. Orion Corp is also a key player in asthma treatment. The company produces medications that expand the airways and make breathing easier. In the diagnostics division, Orion Corp's main business is the development and manufacturing of diagnostic devices for diseases such as lung cancer and asthma, as well as products for monitoring blood sugar and cholesterol. Animal health is another important business area for Orion Corp. The company manufactures medications and accessories for animal health and offers a variety of products to veterinarians and breeders. These include, for example, animal vaccines or hormone preparations to increase fertility in animals. Orion's production facilities are located in six countries, including Finland, Germany, France, Russia, the USA, and India. Production within the company primarily takes place in Finland. In addition to manufacturing medications and medical devices, Orion Corp is also a leading producer and developer of raw materials and intermediates for pharmaceutical applications worldwide. In summary, Orion Corp offers a wide range of products and services in the health and animal health fields using the latest scientific knowledge and technologies. The company remains committed to continuously expanding its product and service portfolio and providing patients worldwide with high-quality and effective medications that positively impact their lives. Orion is one of the most popular companies on Eulerpool.

ROE Details

Decoding Orion's Return on Equity (ROE)

Orion's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Orion's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Orion's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Orion’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Orion stock

Return on Equity (ROE) of Orion is 10.05 % in 2025.

Return on Equity (ROE) of Orion changed from 15.11 % to 10.05 %, representing a -33.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Orion since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Orion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Orion

All Key Metrics — Orion